This lawsuit asserts that Defendants violated certain state antitrust, consumer protection, and unjust enrichment laws in the
United States, harming competition and causing class members to overpay for
Suboxone. Defendants deny that they violated any laws.
All persons or entities who purchased and/or paid for some or all of the purchase price for Co-Formulated
Buprenorphine/Naloxone (Suboxone and/or its AB-rated generic equivalent) in any form, for consumption by themselves,
their families or their members, employees, plan participants, beneficiaries or insureds in
Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois,
Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana,
Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Oklahoma, Oregon,
Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington,
West Virginia, Wisconsin, Wyoming and District of Columbia
between December 22, 2011 and August 21, 2023.
The Settlement provides for Indivior’s payment of $30 million into a Settlement Fund for distribution to End Payor Class members submitting
valid claim forms, attorneys’ fees, the expenses of litigation (including costs of Notice), and service awards to the named Plaintiffs, all
of which is subject to final approval by the Court. The Court has scheduled a hearing (the “Fairness Hearing”) to consider whether to grant
such final approval. The Fairness Hearing is scheduled for October 19, 2023, at 1:30 p.m., before Judge Mitchell S. Goldberg at the James A.
Byrne U.S. Courthouse, 601 Market Street, Philadelphia, PA 19106.